To complement these clinical trials results, the FIRE study was set up to investigate, in France, in real-life conditions, the effectiveness and safety of ibrutinib treatment in patients with CLL (including small lymphocytic lymphoma (SLL)), along with those with high-risk features (e.g. deletion (del)17p or tumor protein p53 (TP53) mutation; unmutated immunoglobulin heavy chain (IGHV) genes). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.